Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial.
Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD.
Patil ST, et al. Among authors: martenyi f.
Nat Med. 2007 Sep;13(9):1102-7. doi: 10.1038/nm1632. Epub 2007 Sep 2.
Nat Med. 2007.
PMID: 17767166
Clinical Trial.